Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics N.V (PRQR) Net Income towards Common Stockholders: 2021-2025

Historic Net Income towards Common Stockholders for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to -$12.9 million.

  • ProQR Therapeutics N.V's Net Income towards Common Stockholders fell 38.37% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.3 million, marking a year-over-year decrease of 86.78%. This contributed to the annual value of -$29.7 million for FY2024, which is 2.46% up from last year.
  • Per ProQR Therapeutics N.V's latest filing, its Net Income towards Common Stockholders stood at -$12.9 million for Q3 2025, which was up 11.43% from -$14.6 million recorded in Q2 2025.
  • In the past 5 years, ProQR Therapeutics N.V's Net Income towards Common Stockholders ranged from a high of -$2.9 million in Q2 2024 and a low of -$23.5 million during Q3 2022.
  • Over the past 3 years, ProQR Therapeutics N.V's median Net Income towards Common Stockholders value was -$9.3 million (recorded in 2024), while the average stood at -$9.0 million.
  • In the last 5 years, ProQR Therapeutics N.V's Net Income towards Common Stockholders soared by 72.01% in 2023 and then slumped by 402.18% in 2025.
  • Over the past 5 years, ProQR Therapeutics N.V's Net Income towards Common Stockholders (Quarterly) stood at -$20.8 million in 2021, then spiked by 34.92% to -$13.6 million in 2022, then surged by 60.85% to -$5.3 million in 2023, then tumbled by 85.19% to -$9.8 million in 2024, then plummeted by 38.37% to -$12.9 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$12.9 million for Q3 2025, versus -$14.6 million for Q2 2025 and -$11.0 million for Q1 2025.